---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report. Covers Cost-effectiveness evidence and Budget impact model. 47 evidence topics quoted from 22 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: ICER assessment, other published economic evaluations, and commercial forecasts

The Institute for Clinical and Economic Review (ICER) assessed baxdrostat and lorundrostat for hypertension in a 2026 evidence report discussed at the “Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension”. The assessment page lists a “Final Evidence Report and Meeting Summary”, and ICER's meeting slides state that the final report would be published “on or around November 30, 2026”. ICER rated the evidence for lorundrostat or baxdrostat compared with spironolactone, eplerenone, or amiloride as “Promising but Inconclusive” in participants with resistant hypertension or intolerance of a third first-line drug (Populations 1 and 2), as “comparable or inferior” to amlodipine in participants not yet treated with a third drug (Population 3), and as insufficient to distinguish lorundrostat from baxdrostat. ICER's lifetime model used the 50 mg once-daily dose of lorundrostat and a placeholder price equal to the baxdrostat wholesale acquisition cost ($10,950 per year). At that price, lorundrostat cost $1,419,000 per QALY gained compared with spironolactone and $1,492,000 compared with amiloride, and was “More costly, less effective” than eplerenone, which ICER attributed to a 10% first-cycle discontinuation probability for lorundrostat against 7.7% for eplerenone. Lorundrostat was cost-effective in 0.0% of probabilistic simulations at $150,000 per evLY gained, and the health-benefit price benchmark for lorundrostat was $760 to $1,600 per year (85.7% to 93.0% below the placeholder price), against $1,400 to $2,500 per year for baxdrostat. Mineralys commented that the model “does not fully capture the clinical and economic benefits of ASIs”, that first-cycle discontinuation of lorundrostat (10%) was based on Launch-HTN and that of eplerenone and amiloride (7.7%) on a study of Swedish patients receiving calcium channel blockers, and that models should incorporate dynamic pricing; a commenting coalition, No Patient Left Behind, estimated a societal value-based price of $18,767 to $26,913 per year. A 2026 review states that cost-effectiveness evidence for aldosterone synthase inhibitors is still needed. No published cost-effectiveness analysis of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension was identified; a 2026 systematic review found 21 modelling studies in treatment-resistant and uncontrolled hypertension, 12 of 14 cost-utility analyses evaluating renal denervation. Published analyses report $32,732 per QALY for radiofrequency renal denervation (Medicare payer perspective), $12,900 per QALY for ultrasound renal denervation, $3,071 per QALY in a 2012 societal-perspective model in resistant hypertension, $4,400 per QALY for team-based care with non-physician titration, and cost savings of $10,162 per person for pharmacist prescribing. No sales forecast from Mineralys was identified; GlobalData forecast lorundrostat sales of $601 million in 2030, and Visible Alpha consensus projected risk-adjusted sales of $122 million in 2027 and $365 million in 2028, with analysts expecting annual revenue of $1.1 billion by 2030.

Source: [ICER hypertension assessment page (2026)](https://icer.org/assessment/hypertension-2026/); [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf); [Baker (2026)](https://pubmed.ncbi.nlm.nih.gov/42847224/); [Franklin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375916/); [Kandzari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11549517/); [Taylor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12230492/); [Geisler et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22981547/); [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/); [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/); [Beaney (2025)](https://www.clinicaltrialsarena.com/news/mineralys-therapeutics-stock-jumps-hypertension-trial-data/); [S&P Global Market Intelligence (2026)](https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/07/astrazeneca-s-baxfendy-set-for-blockbuster-sales-after-hypertension-approval)

<a id="topic-4.1-2"></a>

#### ICER assessment status

> “An assessment of baxdrostat and lorundrostat”
> “Final Evidence Report and Meeting Summary”
> “The Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension:”

Source: [ICER hypertension assessment page (2026)](https://icer.org/assessment/hypertension-2026/)

> “Final Report published on or around November 30, 2026”
> “Includes description of Midwest CEPAC votes, deliberation, policy roundtable discussion”

Source: [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf)

<a id="topic-4.1-3"></a>

#### ICER evidence ratings

> “Our analyses of currently available data did not show differences in effect between ASIs; thus, for all three populations, current data are “insufficient” (I) to determine the net health benefits of baxdrostat and lorundrostat compared with each other.”
> “For patients with resistant hypertension not at goal and those on two antihypertensive medications who did not tolerate a third first-line treatment (Populations 1 and 2), our analyses found no statistically significant difference in blood pressure lowering between all agents. However, ASIs such as baxdrostat and lorundrostat may be better tolerated than spironolactone and may result in greater blood pressure reductions than comparator drugs, though trials are only short-term. Thus, for these Populations, we conclude that the net health benefits of baxdrostat or lorundrostat are “Promising but Inconclusive” (P/I) compared with spironolactone, eplerenone, or amiloride.”
> “In the absence of convincing outcomes data with the ASIs, we feel that, compared with amlodipine, the net health benefit of baxdrostat or lorundrostat is “comparable or inferior” (C-).”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-4"></a>

#### ICER cost-effectiveness model: structure, perspective, and populations

> “We developed a de novo decision analytic model for this evaluation, informed by key clinical trials and prior relevant economic models”
> “Costs and outcomes were discounted at 3% per year. Model cycle length was three months. The analysis was conducted from a US health care sector perspective over a lifetime time horizon.”
> “Populations 1 and 2 were therefore reduced to a single modeled population. Population 3 was not modeled as the comparative effectiveness review rated baxdrostat and lorundrostat as “comparable or inferior” to amlodipine and, consistent with the Model Analysis Plan, cost-effectiveness in this population was to be evaluated only if the aldosterone synthase inhibitors were superior to amlodipine.”
> “As shown in Figure 4.1, the model included seven primary health states: 1) hypertension alone, 2) stroke, 3) myocardial infarction (MI), 4) other symptomatic coronary heart disease (CHD), 5) heart failure (HF), 6) end-stage kidney disease (ESKD), and 7) death.”
> “Baseline characteristics were informed by the Bax24, BaxHTN, and Launch-HTN clinical trials”
> “For each intervention we modeled the dose most likely to be used in clinical practice, namely the 50 mg dose for lorundrostat and the 2 mg dose for baxdrostat, both administered as once daily tablets.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-5"></a>

#### ICER cost-effectiveness model: treatment effect inputs

> “Each treatment’s effect was estimated and modeled through its SBP reduction from ICER’s internal NMA (Table 4.2).”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Parameter | Quoted input |
| --- | --- |
| SBP reduction for lorundrostat vs. placebo (mm Hg) | “9.0, (95% CrI: 1.7, 16.4)” |
| SBP reduction for baxdrostat vs. placebo (mm Hg) | “11.0 (95% CrI: 7.3, 14.6)” |
| SBP reduction for spironolactone vs. placebo (mm Hg) | “10.1 (95% CrI: 6.7, 13.1)” |
| SBP reduction for eplerenone vs. placebo (mm Hg) | “8.8 (95% CrI: 2.3, 15.5)” |
| SBP reduction for amiloride vs. placebo (mm Hg) | “6.6 (95% CrI: 1.4, 11.6)” |
| Hazard ratio for stroke, per 5 mm Hg SBP reduction | “0.87 (95% CI: 0.84, 0.91)” |
| Hazard ratio for ischemic heart disease, per 5 mm Hg SBP reduction | “0.92 (95% CI: 0.89, 0.95)” |
| Hazard ratio for heart failure, per 5 mm Hg SBP reduction | “0.87 (95% CI: 0.83, 0.92)” |
| Relative risk for ESKD, per 10 mm Hg SBP reduction | “0.95 (95% CI: 0.84, 1.07)” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-6"></a>

#### ICER cost-effectiveness model: base-case results at the placeholder price

> “Over a lifetime horizon, treatment with baxdrostat led to small evLY, QALY, and LY gains compared to the three comparators. Treatment with lorundrostat led to similar gains, except compared to eplerenone, where eplerenone had slightly better outcomes at a lower cost.”
> “lorundrostat was modelled with higher discontinuation probability after three months or one cycle (10% based on Launch-HTN) than eplerenone (7.7% from the literature-based persistence curve), which made it less effective and more costly than eplerenone in the base case.”
> “Compared to the comparators, the total costs were higher for baxdrostat and lorundrostat, driven primarily by the higher drug costs.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Treatment | Intervention acquisition costs | Non-intervention costs | Total costs | QALYs | evLYs | LYs |
| --- | --- | --- | --- | --- | --- | --- |
| Lorundrostat (placeholder price) | “$28,500” | “$122,200” | “$150,700” | “9.54” | “9.54” | “11.86” |
| Baxdrostat | “$27,600” | “$122,000” | “$149,600” | “9.55” | “9.55” | “11.87” |
| Spironolactone | “$200” | “$122,600” | “$122,800” | “9.52” | “9.52” | “11.83” |
| Eplerenone | “$2,000” | “$122,200” | “$124,300” | “9.54” | “9.54” | “11.86” |
| Amiloride | “$830” | “$122,500” | “$123,400” | “9.52” | “9.52” | “11.84” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Treatment and comparator | Cost per QALY gained | Cost per evLY gained | Cost per life year gained |
| --- | --- | --- | --- |
| Lorundrostat (placeholder price) vs. spironolactone | “$1,419,000” | “$1,327,000” | “$1,213,000” |
| Lorundrostat (placeholder price) vs. eplerenone | “More costly, less effective” | “More costly, less effective” | “More costly, less effective” |
| Lorundrostat (placeholder price) vs. amiloride | “$1,492,000” | “$1,403,000” | “$1,273,000” |
| Baxdrostat vs. spironolactone | “$833,000” | “$781,000” | “$712,000” |
| Baxdrostat vs. eplerenone | “$2,077,000” | “$1,954,000” | “$1,774,000” |
| Baxdrostat vs. amiloride | “$851,000” | “$800,000” | “$727,000” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-7"></a>

#### ICER cost-effectiveness model: sensitivity and probabilistic analyses

> “For lorundrostat, the range of incremental evLYs gained crossed zero when its SBP reduction was varied.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Lorundrostat (placeholder price) compared with | Cost-effective at $50,000 per evLY gained | Cost-effective at $100,000 per evLY gained | Cost-effective at $150,000 per evLY gained | Cost-effective at $200,000 per evLY gained |
| --- | --- | --- | --- | --- |
| Spironolactone | “0.0%” | “0.0%” | “0.0%” | “0.0%” |
| Eplerenone | “0.0%” | “0.0%” | “0.0%” | “0.2%” |
| Amiloride | “0.0%” | “0.0%” | “0.0%” | “0.2%” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-8"></a>

#### ICER cost-effectiveness model: scenario analyses

> “While the incremental cost-effectiveness ratios improved slightly in the modified societal and the same treatment discontinuation scenarios, they were still well above commonly accepted threshold ranges.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Scenario (cost per QALY gained, lorundrostat at the placeholder price) | Compared with spironolactone | Compared with eplerenone | Compared with amiloride |
| --- | --- | --- | --- |
| Modified societal perspective | “$1,404,000” | “Lower effect, higher cost” | “$1,479,000” |
| Same discontinuation for all treatments | “$1,322,000” | “$16,455,000” | “$1,382,000” |
| No discontinuation for all treatments | “Lower effect, higher cost” | “$16,956,000” | “$1,436,000” |
| 10-year treatment effect duration | “$1,698,000” | “Lower effect, higher cost” | “$1,577,000” |
| 20-year treatment effect duration | “$1,437,000” | “Lower effect, higher cost” | “$1,498,000” |
| 5-year time horizon | “$28,854,000” | “$166,418,000” | “$10,593,000” |
| 10-year time horizon | “$5,392,000” | “$123,253,000” | “$3,622,000” |
| Minimum price for generic comparators | “$1,428,000” | “Lower effect, higher cost” | “$1,521,000” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-9"></a>

#### ICER health-benefit price benchmark and threshold prices

> “The Health Benefit Price Benchmark (HBPB) for a drug is defined as the price range that would achieve incremental cost-effectiveness ratios between $100,000 per QALY gained and $150,000 per evLY gained. The HBPB for baxdrostat is $1,400 to $2,500 per year and for lorundrostat is $760 to $1,600 per year.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Intervention and outcome measure | Annual WAC | Annual price at $100,000 threshold | Annual price at $150,000 threshold | Discount from WAC to reach threshold prices |
| --- | --- | --- | --- | --- |
| Lorundrostat, QALYs gained (placeholder price) | “$10,950” | “$760” | “$1,500” | “86.3% - 93.0%” |
| Lorundrostat, evLYs gained (placeholder price) | “$10,950” | “$770” | “$1,600” | “85.7% - 93.0%” |
| Baxdrostat, QALYs gained | “$10,950” | “$1,400” | “$2,400” | “78.3% - 87.4%” |
| Baxdrostat, evLYs gained | “$10,950” | “$1,400” | “$2,500” | “77.2% - 87.1%” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Lorundrostat compared with (QALY-based) | Annual price to achieve $50,000 per QALY gained | Annual price to achieve $100,000 per QALY gained | Annual price to achieve $150,000 per QALY gained | Annual price to achieve $200,000 per QALY gained |
| --- | --- | --- | --- | --- |
| Spironolactone | “$600” | “$980” | “$1,400” | “$1,700” |
| Eplerenone | “$770” | “$770” | “$760” | “$760” |
| Amiloride | “$790” | “$1,100” | “$1,500” | “$1,900” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-10"></a>

#### ICER cost-effectiveness model: limitations and conclusion

> “SBP reductions for each treatment were estimated from ICER’s internal NMA rather than from head-to-head trials. Because these estimates relied on indirect comparisons rather than head-to-head evidence, several treatment effects, particularly lorundrostat, eplerenone, and amiloride, had wide credible intervals, representing uncertainty in the relative treatment effects that drove the cost-effectiveness results.”
> “The baxdrostat and lorundrostat trials measured SBP reductions rather than cardiovascular and kidney events. The model translated these reductions into changes in event risk using HRs and RR from the BPLTTC meta-analysis. The assumption that this SBP to event relationship applies to aldosterone synthase inhibitors is not confirmed.”
> “At their current WAC-based price and placeholder price, the incremental cost-effectiveness ratios for baxdrostat and lorundrostat were well above commonly used cost-effectiveness thresholds.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-11"></a>

#### ICER comparison with prior economic models

> “These projections were consistent with comparable US cost-effectiveness analyses of hypertension conducted over a lifetime horizon at a 3% discount rate.”
> “Geisler et al. (2012) was the original model that used this assessment’s model schematic in a population of resistant hypertension, and they reported a median survival of 17.1 years for standard of care with a cohort entering their model at 58 years old”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.1-12"></a>

#### Manufacturer comments on the ICER draft evidence report

> “ICER’s economic model does not fully capture the clinical and economic benefits of ASIs for patients with HTN.”
> “Mineralys strongly recommends that ICER remove amiloride and eplerenone as comparators in this review.”
> “In the base-case analysis, discontinuation of lorundrostat in the first three months is estimated to be 10% based on data from Launch-HTN, whereas the discontinuation rate of eplerenone and amiloride was 7.7%, based on a real-world study that examined Swedish patients receiving calcium channel blockers.”
> “As ASIs are subject to price declines due to market dynamics and eventual genericization, models should incorporate dynamic pricing, rather than constant lifetime pricing, to avoid overstating long-term costs.”

Source: [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf)

<a id="topic-4.1-13"></a>

#### ICER responses to the manufacturer comments

> “We selected our source study because it aligned well with the disease status of our patient population and provided sufficient data to construct a discontinuation function.”
> “Finally, we tested several scenarios around our discontinuation assumption, and none changed our conclusion.”
> “Consistent with best practices in HTA, ICER does not as a rule consider “dynamic pricing” in economic evaluation unless there is known timing for patent expiry and certainty around expected changes in price (both during the period of patent protection and following generic entry).”

Source: [ICER response to public comments (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public_Comment_Grid-For-Publication-102626.pdf)

<a id="topic-4.1-14"></a>

#### Stakeholder exploratory analyses of dynamic pricing and societal value

> “No Patient Left Behind (NPLB) is a nonprofit coalition of biotechnology innovators, investors, healthcare professionals, economists, and patient advocates working to ensure that patients have access to the medicines they need today and in the future.”
> “Adjusting these two assumptions alone moved the published ratios by 30–48% in the base case and up to 70% under ICER's own no-discontinuation scenario.”
> “The findings suggest that the societal value-based price for lorundrostat ranges from $18,767 per year (base case) to $26,913 per year (optimistic case).”

Source: [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf)

<a id="topic-4.1-15"></a>

#### Published cost-effectiveness analyses of lorundrostat other than the ICER assessment

No evidence found.

<a id="topic-4.1-16"></a>

#### Cost-effectiveness evidence needed for aldosterone synthase inhibitors

> “The ASIs represent a promising class of antihypertensive drug classes with proven efficacy in reducing both office and ambulatory blood pressure, although studies on their comparative efficacy and safety with MRAs such as spironolactone are needed, along with evidence of cost-effectiveness.”

Source: [Baker (2026)](https://pubmed.ncbi.nlm.nih.gov/42847224/)

<a id="topic-4.1-17"></a>

#### Published cost-effectiveness analyses of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension

No evidence found.

<a id="topic-4.1-18"></a>

#### Systematic review of economic models in treatment-resistant and uncontrolled hypertension

> “A total of 21 modelling studies were included: 16 economic evaluations (14 cost-utility analyses, 1 cost-effectiveness analysis and 1 cost-minimization analysis), 4 burden-of-illness studies and 1 budget impact analysis.”
> “Of the 14 CUAs, 12 evaluated RDN: of these, 7 evaluations comparing radio frequency (RF) RDN plus standard of care (SoC) to SoC alone in different healthcare settings were based on the same model”
> “Although models were generally assessed to be of good quality, models incorporated health-related quality of life and cost data from controlled hypertensive or non-hypertensive populations, rather than those with ucHTN and trHTN.”

Source: [Franklin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375916/)

<a id="topic-4.1-19"></a>

#### Radiofrequency renal denervation, United States Medicare payer perspective

> “A decision-analytic Markov model projected costs, quality-adjusted life years (QALY), and clinical events for an active cohort treated with RF RDN and a control cohort treated with standard-of-care (defined as 1, 2, or 3 antihypertensive medications).”
> “The model projected costs and effects with a lifetime horizon from a Medicare payer perspective.”
> “Over lifetime, RF RDN added 0.34 QALY at an additional cost of $11,275, leading to an incremental cost-effectiveness ratio of $32,732 per QALY.”

Source: [Kandzari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11549517/)

<a id="topic-4.1-20"></a>

#### Ultrasound renal denervation, United States health care system perspective

> “A previously published Markov model was adapted to compare total costs and quality-adjusted life years (QALY) between uRDN plus standard of care (SoC) vs SoC alone over a lifetime horizon from a US health care system perspective.”
> “Using a procedure cost of $23,000, total lifetime costs were higher with the uRDN procedure (uRDN plus SoC: $110,476 vs SoC alone: $102,875), resulting in an incremental cost-effectiveness ratio of $12,900 per QALY.”

Source: [Taylor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12230492/)

<a id="topic-4.1-21"></a>

#### Catheter-based renal denervation for resistant hypertension, first United States model

> “We adopted a societal perspective and estimated an incremental cost-effectiveness ratio in U.S. dollars per quality-adjusted life-year, both discounted at 3% per year.”
> “The discounted lifetime incremental cost-effectiveness ratio was $3,071 per quality-adjusted life-year.”

Source: [Geisler et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22981547/)

<a id="topic-4.1-22"></a>

#### Team-based care with non-physician medication titration, United States

> “Relative to usual care at 10 years, TBC with non-physician titration was estimated to cost $95 (95% uncertainty interval: -$563 to $664) more per patient and gain 0.022 (0.003 to 0.042) QALYs, costing $4,400/QALY gained.”

Source: [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/)

<a id="topic-4.1-23"></a>

#### Pharmacist prescribing for hypertension, United States

> “The intervention was also associated with 0.34 (2.5th-97.5th percentiles, 0.23-0.45) additional life years and 0.62 (2.5th-97.5th percentiles, 0.53-0.73) additional QALYs.”
> “The cost savings were $10 162 (2.5th-97.5th percentiles, $6636-$13 581) per person due to fewer CV events with the pharmacist-prescribing intervention, even after the cost of the visits and medication adjustments.”

Source: [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/)

<a id="topic-4.1-24"></a>

#### Forecast sales of lorundrostat

> “According to GlobalData forecasts, sales of lorundrostat could reach $601m in 2030.”

Source: [Beaney (2025)](https://www.clinicaltrialsarena.com/news/mineralys-therapeutics-stock-jumps-hypertension-trial-data/)

> “Visible Alpha consensus assigns lorundrostat a 90% probability of US approval in the indication, with risk-adjusted sales projected at $122 million in 2027, pending approval, and $365 million in 2028. Analysts expect the drug to reach blockbuster status by 2030, with annual revenue of $1.1 billion.”
> “Visible Alpha consensus reflects that advantage, with Baxfendy projected to establish a clear lead in the ASI market and generate substantially higher sales than lorundrostat over the remainder of the decade.”

Source: [S&P Global Market Intelligence (2026)](https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/07/astrazeneca-s-baxfendy-set-for-blockbuster-sales-after-hypertension-approval)

<a id="topic-4.1-25"></a>

#### Manufacturer statements on the market opportunity

> “Over 30 million hypertensive patients in the United States are unable to achieve their BP goal despite treatment, and within this population, 10 million suffer from rHTN”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “we clearly see a significant market opportunity here with, as we stated before, about 20 million patients in the United States alone dealing with uncontrolled and resistant hypertension.”
> “There is certainly room for two novel therapeutics in what I think may be a transformative class overall.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

<a id="topic-4.2.1-1"></a>

##### ICER potential budget impact analysis: definition and comparator mix

> “Results from the cost-effectiveness model were used to calculate the total potential budgetary impact of baxdrostat and lorundrostat for the population of US adults with uncontrolled or resistant hypertension. Potential budget impact is defined as the total differential cost of using the new therapy rather than a relevant existing therapy for the treated population, calculated as health care costs (including drug costs) minus any offsets in these costs from averted health care events. We used an even split of spironolactone, eplerenone, and amiloride as the baseline comparator.”
> “The intent of our approach to budgetary impact is to document the percentage of patients that could be treated at selected prices without crossing a budget impact threshold that represents a potential trigger for policy mechanisms to improve affordability, such as changes to pricing, payment, or patient eligibility.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.1-2"></a>

##### Derivation of the potential budget impact threshold

> “this threshold is based on an underlying assumption that health care costs should not grow much faster than growth in the overall national economy. From this foundational assumption, our potential budget impact threshold is derived using an estimate of growth in US gross domestic product (GDP) +1%, the average number of new drug approvals by the FDA over the most recent five-year period, and the contribution of spending on retail and facility-based drugs to total health care spending.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

<a id="topic-4.2.2-1"></a>

##### ICER potential budget impact analysis: time horizon and discounting

> “All costs were undiscounted and estimated over a five-year time horizon.”
> “All costs were undiscounted and estimated over one- and five-year time horizons.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.2-2"></a>

##### ICER cost-effectiveness model underlying the budget impact analysis: perspective

> “The analysis was conducted from a US health care sector perspective over a lifetime time horizon.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

##### ICER potential budget impact analysis: populations included

> “This includes the resistant hypertension population consisting of those on three or more antihypertensive medications and not meeting blood pressure goals (Population 1), and the population on two antihypertensive medications and not meeting blood pressure goals who did not tolerate a third medication (Population 2). We did not estimate the budget impact for the population of those on two antihypertensive medications and not meeting blood pressure goals who have not tried a third first-line medication (Population 3) because this specific population was not modeled in the cost-effectiveness model.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.3-2"></a>

##### ICER potential budget impact analysis: eligible population and uptake

> “To estimate the size of Population 1 (those taking three or more antihypertensive medications but still not achieving blood pressure goals), we used inputs for the overall prevalence of hypertension among US adults (48.1%)”
> “the percentage of those with hypertension who are taking medication (51.2%)”
> “and the percentage of those taking medication who are being treated with three or more antihypertensive medications but still have uncontrolled hypertension (15%)”
> “Applying these sources to the overall adult population in the US averaged over the next five years (271,862,765) results in estimates of 10,042,828 eligible patients in the US. For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 2,008,565 patients per year.”
> “who are being treated with two antihypertensive medications and still have uncontrolled hypertension (17.9%)”
> “We then assumed that 21% of these have attempted a third antihypertensive medication and discontinued. This is a placeholder estimate based on available claims data reporting discontinuation rate of antihypertensive medications”
> “As a result, we estimated that 2,516,732 patients have uncontrolled hypertension and have attempted and discontinued a third antihypertensive medication (Population 2). For the purposes of this analysis, we assumed that 20% of these patients would initiate treatment in each of the five years, or 503,346 patients per year. Between Population 1 and Population 2 we estimated a total of 12,559,560 eligible patients.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.3-3"></a>

##### Source of the treated proportion used by ICER

> “More than one-half of adults with hypertension were currently taking medication (51.2%) to lower blood pressure.”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-4.2.3-4"></a>

##### Patient funnel for a hypothetical 1 million–member United States health plan

> “Based on US census and literature data, among a hypothetical 1 million–member US health plan, 194 140 individuals are adults diagnosed and treated for HTN.”
> “Based on Optum Market Clarity Data used in this study, 53.8% of treated patients have uHTN, corresponding to 104 494 patients in the standardized funnel.”
> “Among patients with uHTN, 64.7% receive 2+ AHTs (n = 67 584), of whom 45.1% receive 2 AHTs (n = 30 503) and 54.9% receive 3+ AHTs (n = 37 081).”
> “This patient funnel provides estimates of uHTN and rHTN prevalence among adult patients with HTN based on large-scale real-world data (i.e., 27.6% and 9.8%, respectively).”
> “The standardized HTN patient funnel can inform future economic analyses estimating the financial impact of interventions aimed at improving HTN management and patient care.”

Source: [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf)

<a id="topic-4.2.3-5"></a>

##### Manufacturer target population and prescriber base

> “That is that third line or later. We think resistant is the natural opening space, and with experience, both from a physician standpoint and demand growing into the third-line usage.”
> “As you have heard us say before, when we look at where we have developed this molecule, third line or later, and in the United States who prescribes there, it is about 60,000 physicians that are responsible for half of the scripts third line or later.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

##### ICER drug prices: baxdrostat, lorundrostat placeholder, and generic comparators

> “For baxdrostat, we used the wholesale acquisition cost (WAC) price from RedBook ($900 for 30 tablets). Given that baxdrostat was recently launched, and no information is available to inform a discount from WAC, the WAC price was used as the net price. For lorundrostat, we used the baxdrostat WAC price as a placeholder price. For comparator drugs (spironolactone, eplerenone, and amiloride) we obtained net pricing estimates from Redbook based on the median cost (WAC) across all generic versions.”
> “We used the net prices and the threshold prices (at $50,000, $100,000, $150,000, and $200,000 per evLY gained) for baxdrostat and lorundrostat when compared to each comparator to estimate the percentage of the eligible population that could be treated before reaching the ICER potential budget impact threshold of $821 million.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Drug | WAC per dose | Net price per dose | Net price per year |
| --- | --- | --- | --- |
| Spironolactone (25 mg) | “$0.117” | “$0.117” | “$43” |
| Spironolactone (100 mg) | “$0.4683” | “$0.4683” | “$171” |
| Eplerenone (50 mg) | “$1.3997” | “$1.3997” | “$511” |
| Eplerenone (100 mg) | “$2.793” | “$2.793” | “$1,022” |
| Amiloride (5 mg) | “$0.5627” | “$0.5627” | “$206” |
| Amiloride (10 mg) | “$1.1253” | “$1.1253” | “$411” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Intervention (dosage) | WAC per dose | Net annual cost | Source |
| --- | --- | --- | --- |
| Lorundrostat (50 mg/day) | “$30” | “$10,950” | “Placeholder” |
| Baxdrostat (2 mg/day) | “$30” | “$10,950” | “Redbook” |
| Spironolactone (25–100 mg/day) | “$0.12–$0.47” | “$43–$171” | “Redbook” |
| Eplerenone (50–100 mg/day) | “$1.40–$2.79” | “$511–$1,022” | “Redbook” |
| Amiloride (5–10 mg/day) | “$0.56–$1.13” | “$206–$411” | “Redbook” |

Source: [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf)

<a id="topic-4.2.4-2"></a>

##### ICER dosing regimens costed

| Drug | Quoted dosing |
| --- | --- |
| Lorundrostat | “50 mg once daily” |
| Baxdrostat | “1 or 2 mg once daily” |
| Spironolactone | “25-100 mg once daily” |
| Eplerenone | “50 mg once to twice daily” |
| Amiloride | “5-10 mg once daily” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.4-3"></a>

##### ICER health state costs

> “Non-drug health care costs were applied as health state costs reflecting the direct medical care associated with each health state in the model.”
> “Included one-time costs of hyperkalemia monitoring ($11) for all five treatments.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Health state | Annual cost (2025 US dollars) |
| --- | --- |
| Hypertension (annual) | “$3,211” |
| Stroke (acute and annual) | “$20,442 / $20,697” |
| Myocardial infarction (acute and annual) | “$25,832 / $17,106” |
| Coronary heart disease (annual) | “$13,798” |
| Heart failure (index hospitalization and annual) | “$16,671 / $33,890” |
| End-stage kidney disease (annual) | “$108,953” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.4-4"></a>

##### Lorundrostat price: manufacturer statements

> “We have talked in the past, Annabel, that as a guidance or a frame for pricing, we have always directed to probably more of an SGLT2-branded price point, Entresto price point, broadly at a WAC, but have not guided as it relates to rebates.”
> “I think we continue to feel very strong about the value proposition of lorundrostat, the need specifically in the resistant hypertension population, and so we believe that both the combination of appropriate price and rebate is going to create that access.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-4.2.4-5"></a>

##### Comparator acquisition cost: National Average Drug Acquisition Cost, spironolactone 25 mg

| Field | Quoted record |
| --- | --- |
| NDC description | “SPIRONOLACTONE 25 MG TABLET” |
| NADAC per unit | “0.04218” |
| Effective date | “2026-11-18” |

Source: [CMS NADAC, spironolactone 25 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=53489014310&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="topic-4.2.4-6"></a>

##### Comparator acquisition cost: National Average Drug Acquisition Cost, eplerenone 50 mg

| Field | Quoted record |
| --- | --- |
| NDC description | “EPLERENONE 50 MG TABLET” |
| NADAC per unit | “0.47438” |
| Effective date | “2026-11-18” |

Source: [CMS NADAC, eplerenone 50 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=31722005030&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="topic-4.2.4-7"></a>

##### Comparator acquisition cost: National Average Drug Acquisition Cost, amiloride 5 mg

| Field | Quoted record |
| --- | --- |
| NDC description | “AMILORIDE HCL 5 MG TABLET” |
| NADAC per unit | “0.20688” |
| Effective date | “2026-11-18” |

Source: [CMS NADAC, amiloride 5 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=42794000502&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="topic-4.2.4-8"></a>

##### Comparator acquisition cost: National Average Drug Acquisition Cost, baxdrostat 2 mg

| Field | Quoted record |
| --- | --- |
| NDC description | “BAXFENDY 2 MG TABLET” |
| NADAC per unit | “28.78424” |
| Effective date | “2026-11-18” |

Source: [CMS NADAC, BAXFENDY 2 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=00310600230&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

<a id="topic-4.2.5-1"></a>

##### ICER potential budget impact analysis: outcome measures and threshold

> “The cumulative per patient budget impact represents the incremental costs of each intervention compared to the baseline per patient across all patients treated within a time horizon (including those who initiated treatment in previous years), assuming baxdrostat and lorundrostat are used with 20% uptake each year over five years.”
> “For 2025-2026, therefore, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately $821 million per year for new drugs.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

<a id="topic-4.2.6.1-1"></a>

###### Lorundrostat at the placeholder price compared with an even split of spironolactone, eplerenone, and amiloride

> “At lorundrostat’s annual placeholder price of $10,950, the cumulative annual budget impact per patient was approximately $8,500 in year one and $16,300 by year five.”
> “At the base case annual placeholder price of $10,950 for lorundrostat, approximately 2% of eligible patients (including both Population 1 and Population 2) could be treated before reaching the ICER potential budget impact threshold of $821 million.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.6.1-2"></a>

###### Baxdrostat at its wholesale acquisition cost compared with the same baseline

> “At baxdrostat’s annual net price of $10,950, the cumulative annual budget impact per patient was approximately $8,300 in year one and $15,700 by year five.”
> “At the base case annual price of $10,950 for baxdrostat, approximately 2% of eligible patients (including both Population 1 and Population 2) could be treated before reaching the ICER potential budget impact threshold of $821 million.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

<a id="topic-4.2.6.2-1"></a>

###### Lorundrostat at cost-effectiveness threshold prices

> “100% of eligible patients could be treated at all threshold prices for lorundrostat when compared to eplerenone. 100% of the eligible population could also be treated at the $50,000 per evLY threshold price when compared to spironolactone ($630), and amiloride ($810). At the $200,000 per evLY threshold price when compared to spironolactone ($1,800) and amiloride ($1,900), approximately 17%, and 15% of eligible patients could be treated respectively.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.6.2-2"></a>

###### Baxdrostat at cost-effectiveness threshold prices

> “At the $50,000 per evLY threshold price when compared to spironolactone ($1,000), eplerenone ($1,200), and amiloride ($1,200), approximately 55%, 45%, and 45% of eligible patients could be treated respectively. At the $200,000 per evLY threshold price when compared to spironolactone ($3,000), eplerenone ($1,900), and amiloride ($3,100), approximately 9%, 17%, and 8% of eligible patients could be treated respectively.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

##### Summary

No budget impact model of lorundrostat from Mineralys or a health plan was identified; the only budget impact analysis is ICER's potential budget impact analysis in its 2026 evidence report, which uses a placeholder price of $10,950 per year equal to the baxdrostat wholesale acquisition cost ($900 for 30 tablets). The analysis takes the cost-effectiveness model's health care costs, undiscounted, over five years, against an even split of spironolactone, eplerenone, and amiloride, whose median generic acquisition costs in ICER's model were $43 to $1,022 per year. It sized 10,042,828 United States adults with resistant hypertension on three or more drugs (Population 1) and 2,516,732 on two drugs who discontinued a third (Population 2, based on a 21% placeholder discontinuation estimate), 12,559,560 in total, and assumed 20% would initiate treatment in each year. At the placeholder price, the cumulative budget impact per patient treated was about $8,500 in year one and $16,300 by year five, and about 2% of eligible patients could be treated before annual spending reached ICER's threshold of $821 million; at the threshold prices, 100% could be treated against eplerenone and at the $50,000 per evLY prices against spironolactone ($630) and amiloride ($810). ICER did not size Population 3, patients on two drugs who have not tried a third, which overlaps the company's stated “third line or later” target. The analysis reports national figures and does not model a health plan membership; a 2026 poster hosted on the Mineralys website estimates, for a hypothetical 1 million–member plan, 194,140 treated adults with hypertension, 104,494 with uncontrolled hypertension, and 37,081 receiving three or more drugs. The actual budget impact will depend on a lorundrostat price not yet announced (Mineralys has referred to an SGLT2 inhibitor or Entresto price point at WAC and has given no rebate guidance), on rebates, and on displacement of baxdrostat, whose NADAC was $28.78424 per 2 mg tablet on 18 November 2026, and of generic mineralocorticoid receptor antagonists and amiloride, whose NADAC ranged from $0.04218 to $0.47438 per tablet.

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf); [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript); [CMS NADAC, BAXFENDY 2 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=00310600230&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, spironolactone 25 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=53489014310&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, eplerenone 50 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=31722005030&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1); [CMS NADAC, amiloride 5 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=42794000502&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="topic-4.2.7-2"></a>

##### Manufacturer comments relevant to the budget impact inputs

> “Third, ICER should incorporate estimates of treatment discontinuation that are specific to the treatment and population being modelled.”
> “Given differences in patient behaviors across geographies and available evidence for the products being considered, as well as the sensitivity of results to the value of this input, we encourage ICER to ensure the best available data is being utilized to prevent biasing results.”

Source: [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
